# US 2019/0315746 A1 · Rutaecarpine analogs and applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315746 A1
- Document ID: US20190315746A1
- Status: Published application
- Kind: A1
- Application number: 15/952,644
- Filed: 2018-04-13
- Published: 2019-10-17
- Earliest claimed: 2018-04-13
- Assignees: Taipei Medical University; National Taipei University of Technology
- Applicants: Taipei Medical University; National Taipei University of Technology
- Inventors: Chun-Mao Lin; Chi-Ming Lee; Chi Wang; Sheng-Tung Huang; Jiun-An Gu; Tin-An Rau
- Web page: https://patentgrep.com/patent/US20190315746A1

## CPC

- C07D 471/14: Ortho-condensed systems
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides RUT analogs with various biological activities. In particular, the biological activities comprise anti-inflammatory activity, vasodilator effects, migration/invasion-suppressive activities, ability against damage due to remodeling between the epithelium and endothelium, collagen deposition and cardiac fibrosis suppress. Snail protein inhibitory effect, etc., which may improve cardiac, vasodilation, and lung functions. The RUT analogs disclosed herein also exhibit a lower cytotoxicity comparing to RUT.

## Claims

### Claim 1

A compound having the following Formula (I),
wherein R represents H or methoxy;
R1 and R2 are each independently selected from H, hydroxyl, halogen, C1-3 alkyl and C1-3 alkoxy;
R3, R4, and R5 are each independently selected from H, hydroxyl, fluoro, C1-3 alkyl and C1-3 alkoxy;
or a solvate, prodrug, stereoisomer, enantiomer, or pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R is methoxy.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R3, R4, and R5 are each H.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R1 and R2 each are H.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R is H.

### Claim 6 (depends on 5)

The compound of claim 5, wherein R3, R4, and R5 are each H.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R1 and R2 each are H.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable ester, salt, or prodrug thereof, together with a pharmaceutically acceptable carrier

### Claim 9 (depends on 1)

A method of ameliorating inflammation in a subject, comprising a step of administering a compound of claim 1 to the subject.

### Claim 10 (depends on 1)

A method of inhibiting cell migration, cell invasion or both in a subject, comprising a step of administering a compound of claim 1 to the subject.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cell is a cancer cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer cell is an ovarian carcinoma cell.

### Claim 13 (depends on 1)

A method of ameliorating damage due to remodeling between the epithelium and endothelium in a subject, comprising a step of administering a compound of claim 1 to the subject.

### Claim 14 (depends on 1)

A method of improving cardiac, vasodilation and/or lung functions of a subject, comprising a step of administering a compound of claim 1 to the subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein the improvement comprises inhibition of fibrosis of heart, blood vessels and/or lung.

### Claim 16

A compound of 10-fluoro-2-methoxyrutaecarpine (F-RUT).

### Claim 17

A compound of 10-fluoro-2,3-dimethoxyrutaecarpine.
